Figures and Tables

From the following article:

Interferons at age 50: past, current and future impact on biomedicine

Ernest C. Borden, Ganes C. Sen, Gilles Uze, Robert H. Silverman, Richard M. Ransohoff, Graham R. Foster & George R. Stark

Nature Reviews Drug Discovery 6, 975-990 (December 2007)

doi:10.1038/nrd2422

Figure 1 - Interferons at age 50: past, current and future impact on biomedicine

Figure 1

Mammalian Toll-like receptors (TLRs) and their ligands.

Figure 2 - Interferons at age 50: past, current and future impact on biomedicine

Figure 2

Different interferon (IFN) signalling pathways activated by dsRNA and viruses.

Figure 3 - Interferons at age 50: past, current and future impact on biomedicine

Figure 3

Receptor activation or ligand–receptor complex assembled by type I, type II or type III interferons.

Figure 4 - Interferons at age 50: past, current and future impact on biomedicine

Figure 4

Complexity of the signalling response.

Figure 5 - Interferons at age 50: past, current and future impact on biomedicine

Figure 5

Potential drug targets in the interferon (IFN) system.

Table 1 - Interferons at age 50: past, current and future impact on biomedicine

Table 1

ISGs in the antiviral and anticancer effects of IFNs